Search Results - targeted+therapy

14 Results Sort By:
Covalent MEK4 Inhibitors for Targeted Cancer Therapy
NU 2025-154 INVENTORS Karl Scheidt* Gina Connors SHORT DESCRIPTION This technology introduces novel covalent inhibitors of MEK4, built upon previously-developed reversible inhibitors (see NU2019-059 and NU2021-217). A covalent inhibition strategy offers enhanced potency, selectivity, and prolonged duration of action compared to reversible...
Published: 12/16/2025   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Covalent Inhibition, Kinase Inhibitor, Leukemia, MEK4, MEK7, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Subgraph Matching for High-Throughput DNA-Aptamer Secondary Structure Classification and Machine Learning Interpretability (Case No. 2025-104)
Intro Sentence: UCLA researchers in the Department of Mathematics have developed machine learning methods to rapidly identify novel aptamer sequences for target binding to accelerate highly-accurate diagnostic and therapeutic development. Background: Aptamers are single-stranded nucleotide polymers that bind with high affinity to targets such as...
Published: 8/19/2025   |   Inventor(s): Andrea Bertozzi, Anne Andrews, Matthew Tyler, Paolo Climaco, Noelle Mitchell
Keywords(s): Advanced Computing / AI, advanced computing methods, Aptamers, Artifical Intelligence (Machine Learning, Data Mining), artificial intelligence/machine learning models, bioinformatics pipeline, cancer target, clustering, computational efficiency, computational efficiency and analysis, design software, DNA clustering, DNA oligomer, DNA Sequencing, Drug, Drug Delivery, Drug Development, Drug Discovery, drug screening, high throughput, high throughput assays, high throughput testing, high-throughput analysis, High-Throughput Screening, interpretability, pipeline, large-scale parallelization, Machine Learning, machine learning modeling, motif structures, open source, open source code, OpenAI, Pharmaceutical Drug, protein classification, secondary structure, SELEX, sequences of interest, single strand DNA sequences, Software, Software & Algorithms, Software Development Tools, Software-enabled learning, subgraph matching, target binding, target detection, Targeted Therapy, Targets And Assays, tissue targeting accuracy
Category(s): Software & Algorithms, Software & Algorithms > AI Algorithms, Software & Algorithms > Artificial Intelligence & Machine Learning, Software & Algorithms > Data Analytics, Life Science Research Tools, Life Science Research Tools > Research Methods, Life Science Research Tools > Screening Libraries, Platforms, Platforms > Drug Delivery, Diagnostic Markers > Targets And Assays, Diagnostic Markers, Software & Algorithms > Bioinformatics
Improved MEK4 Inhibitors for the Treatment of Cancer
NU 2021-217 INVENTORS Karl Scheidt* Ada Jade Kwong Hidayatullah Munshi Thao Nguyen Pham SHORT DESCRIPTION This technology introduces novel indazole derivatives as potent and selective MEK4 inhibitors for cancer treatment, particularly in advanced prostate cancer and pancreatic adenocarcinoma. The lead molecule is optimized over first-generation...
Published: 12/17/2025   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Pancreatic cancer, Prostate cancer, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Cell-type specific disruption of M1 muscarinic acetylcholine receptor expression to alleviate Parkinson's disease
NU 2024-244 INVENTORS Dalton J. Surmeier Jr* Tatiana Tkatch Shenyu Zhai SHORT DESCRIPTION Gene therapy targeting M1 muscarinic receptor expression in striatal spiny projection neurons to enhance levodopa response and slow Parkinson’s Disease progression. BACKGROUND Parkinson’s Disease (PD) is the second most common age-related...
Published: 1/5/2026   |   Inventor(s):  
Keywords(s): CNS - Central Nervous System, Gene therapy, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Gene therapy for levodopa-induced dyskinesia
NU 2024-086 INVENTORS Dalton J. Surmeier Jr* Weixing Shen Shenyu Zhai Tatiana Tkatch Qiaoling Cui Zhong Xie SHORT DESCRIPTION Gene therapy targeting GRIN2B in striatal spiny projection neurons to treat levodopa-induced dyskinesia. BACKGROUND Parkinson’s Disease (PD) is the second most common age-related neurodegenerative disease...
Published: 1/5/2026   |   Inventor(s):  
Keywords(s): CNS - Central Nervous System, Dyskinesis, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Therapeutic Intervention for ALS and Dementia
NU 2021-058 INVENTORS Evangelos Kiskinis* Juan Alberto Ortega Cano Marco Boccitto SHORT DESCRIPTION Design of an RNA-based oligonucleotide that protects from dipeptide repeat protein toxicity for the treatment of ALS and FTD. BACKGROUND Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating neurodegenerative diseases...
Published: 12/18/2025   |   Inventor(s):  
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, CNS - Central Nervous System, DPR - Dipeptide Repeat Proteins, FTD - Frontotemporal Dementia, Neurodegenerative disease, Neurology, RNA - Ribonucleic Acid, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
A Novel “Host-Guest”-Based Supramolecular Hydrogel for Dental Pulp Regeneration (Case No. 2023-154)
Summary: Researchers in the Department of Dentistry at UCLA have developed an innovative hydrogel for a vast array of biomedical and tissue engineering applications. Background: Hydrogels have emerged as powerful tools in biomedical engineering due to their ability to provide a supportive environment for cell growth, tissue repair, and drug delivery....
Published: 4/29/2025   |   Inventor(s): Alireza Moshaverinia, Weihao Yuan
Keywords(s): anti-dehydration, Drug Delivery, dynamic identification, hydrogel, Stem Cells / Regenerative Medicine, Targeted Therapy, tissue regeneration
Category(s): Chemical, Materials > Functional Materials, Platforms > Drug Delivery, Platforms > Drug Delivery > Antibody Delivery Platforms, Platforms > Drug Delivery > Nanoparticles, Platforms > Drug Delivery > Viral Delivery Systems, Therapeutics > Cell Therapy, Therapeutics > Medication, Therapeutics > Stem Cells And Regenerative Medicine
MEK7 inhibitors for acute lymphoblastic leukemia (ALL) treatment
NU 2023-060 INVENTORS Karl Scheidt* Dalton Kim Meghan Orr SHORT DESCRIPTION Rational design of highly potent and selective covalent MEK7 inhibitors BACKGROUND Acute lymphoblastic leukemia (ALL) is a deadly blood cancer, the most common hematological malignancy in patients under 14 years of age. Despite advancements in treatment, ALL relapse...
Published: 12/16/2025   |   Inventor(s):  
Keywords(s): ALL - Acute Lymphoblastic Leukemia, Cancer/Oncology, Leukemia, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Therapy for T-Cell Lymphoma
NU2022-104 INVENTORS Jaehyuk Choi* Jay Daniels Jurgen Ruland Tim Wartweig SHORT DESCRIPTION Targeting PD-1 related mechanisms for treatment of aggressive T-Cell lymphomas BACKGROUND T-cell non-Hodgkin lymphomas (T-NHLs) are highly aggressive cancers that can be resistant to chemotherapies. The molecular pathogenesis of these cancers remains...
Published: 12/15/2025   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Lymphoma, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)
Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment.  The...
Published: 4/23/2025   |   Inventor(s): Scott Durum, Julie Hixon, Wenqing Li, Scotch Walsh, Lila Kashi
Keywords(s): Acute lymphoblastic leukemia (ALL), ANTIBODY, Antibody-Dependent Cellular Cytotoxicity (ADCC), Autoimmunity, CANCER, DIABETES, Durum, Interleukin-7 receptor-α (IL-7Rα), Multiple sclerosis, personalized medicine, Targeted therapy, THERAPY, TRANSPLANTATION
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
1 2